首页> 外文期刊>Advances in Rheumatology >Adverse drug reactions associated with treatment in patients with chronic rheumatic diseases in childhood: a retrospective real life review of a single center cohort
【24h】

Adverse drug reactions associated with treatment in patients with chronic rheumatic diseases in childhood: a retrospective real life review of a single center cohort

机译:与童年慢性风湿病患者治疗相关的不良药物:单一中心队列的回顾性真实综述

获取原文
获取外文期刊封面目录资料

摘要

Adverse drug reactions (ADRs) are the sixth leading causes of death worldwide; monitoring them is fundamental, especially in patients with disorders like chronic rheumatic diseases (CRDs). The study aimed to describe the ADRs investigating their severity and associated factors and resulting interventions in pediatric patients with CRDs. A retrospective, descriptive and analytical study was conducted on a cohort of children and adolescents with juvenile idiopathic arthritis (JIA), juvenile systemic lupus erythematosus (JSLE) and juvenile dermatomyositis (JDM). The study evaluated medical records of the patients to determine the causality and the management of ADRs. In order to investigate the risk factors that would increase the risk of ADRs, a logistic regression model was carried out on a group of patients treated with the main used drug. We observed 949 ADRs in 547 patients studied. Methotrexate (MTX) was the most frequently used medication and also the cause of the most ADRs, which occurred in 63.3% of patients, followed by glucocorticoids (GCs). Comparing synthetic disease-modifying anti-rheumatic drugs (sDMARDs) vs biologic disease-modifying anti-rheumatic drugs (bDMARDs), the ADRs attributed to the former were by far higher than the latter. In general, the severity of ADRs was moderate and manageable. Drug withdrawal occurred in almost a quarter of the cases. In terms of risk factors, most patients who experienced ADRs due to MTX, were 16?years old or younger and received MTX in doses equal or higher than 0.6?mg/kg/week. Patients with JIA and JDM had a lower risk of ADRs than patients with JSLE. In the multiple regression model, the use of GCs for over 6?months led to an increase of 0.5% in the number of ADRs. Although the ADRs highly likely affect a wide range of children and adolescents with CRDs they were considered moderate and manageable cases mostly. However, triggers of ADRs need further investigations.
机译:药品不良反应(ADR)是领先的全球死亡原因的第六;监视它们是根本,尤其是在患者等慢性风湿性疾病(顶层要求)病症。旨在研究来形容不良反应调查其严重程度和相关的因素,并导致儿童患者的干预与顶层要求。回顾性,描述和分析研究是在儿童和青少年的幼年特发性关节炎(JIA),幼年系统性红斑狼疮(JSLE)和儿童皮肌炎(JDM)的一个队列中进行。患者的研究评估医疗记录,以确定因果关系和ADR的管理。为了调查的危险因素会增加不良反应的危险性,逻辑回归模型,对一组与主使用的药物治疗的患者进行。我们观察到在研究547例不良反应949。甲氨蝶呤(MTX)是最常用的药物,也是最ADR的原因,其发生率为63.3%,其次是糖皮质激素(GCS)。比较合成疾病的抗风湿药(sDMARDs)与生物疾病的抗风湿药(bDMARDs),归因于前者的不良反应均远远高于后者。在一般情况下,药物不良反应的严重程度为中等和管理。停药发生在差不多的情况下四分之一。在风险因素,谁经历不良反应是由于MTX大多数患者而言,分别为16?岁或更年轻,接受MTX剂量等于或高于0.6?毫克/千克/周。患者贾和JDM有不良反应患者除JSLE的风险较低。在多元回归模型,对超过6个半月使用的GC导致不良反应的人数同比增加0.5%。虽然不良反应极有可能影响广泛的儿童和青少年与顶层要求他们大多认为是温和的和可管理的情况。然而,不良反应的触发需要进一步调查。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号